A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status:
Withdrawn
Trial end date:
2019-07-08
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of
bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular
hypertension.